Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07144813 · ClinicalTrials.gov registry record · NA
Post-Approval Study of the Neuspera Sacral Neuromodulation System
A NA study of Urinary Urgency Incontinence, sponsored by Neuspera Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 116
- Enrollment target
- 20
- Study locations
NCT07144813: Recruiting NA study of Urinary Urgency Incontinence, sponsored by Neuspera Medical.
NCT07144813 is a NA study of Urinary Urgency Incontinence that is actively recruiting participants, run by Neuspera Medical. The registered enrollment target is 116 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07144813, a NA study of Urinary Urgency Incontinence, is actively recruiting participants, sponsored by Neuspera Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 116 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, multi-center, single-arm, post-approval study is designed to assess the long-term safety and efficacy data of the Neuspera Sacral Neuromodulation (SNM) System following commercial approval of the Neuspera SNM System. Participants in this study received intervention/implanted in Phase I or Phase II of the Neuspera SANS\_UUI (NSM-004) Study.
Primary Outcome
Incidence of device- and procedure-related AEs
Conditions Studied
Interventions
- DEVICE Neuspera Implantable Sacral Neuromodulation System
Study Locations (20)
California
- Kaiser Permanente Point Loma MOB - San Diego
- Genesis Healthcare Partners - San Diego
Indiana
- Women's Health Advantage, - Fort Wayne
- Indiana University, School of Medicine - Indianapolis
Texas
- Urology Austin, - Austin
- UCNT Dallas, - Dallas
Florida
- Florida Urology Partners - Tampa
Kansas
- University of Kansas Medical Center, - Kansas City
Kentucky
- University of Louisville Health System, - Louisville
Louisiana
- Ochsner Medical - New Orleans
Michigan
- University of Michigan Health - Wyoming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2029-12 |
| Phase | NA |
What NCT07144813 shows while recruiting
NCT07144813 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Urinary Urgency Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Neuspera Implantable Sacral Neuromodulation System is the first listed.
NCT07144813 names 20 study sites across 17 states, led by California, Indiana, Texas.
Frequently Asked Questions
What is clinical trial NCT07144813 about?
NCT07144813 is a clinical study titled "Post-Approval Study of the Neuspera Sacral Neuromodulation System". Prospective, multi-center, single-arm, post-approval study is designed to assess the long-term safety and efficacy data of the Neuspera Sacral Neuromodulation (SNM) System following commercial approval of the Neuspera SNM System. Participants in this study received intervention/implanted in Phase I...
What is the current status of trial NCT07144813?
This trial is currently recruiting. It is a NA study. The enrollment target is 116 participants. The study started on 2025-09-03. Estimated completion is 2029-12.
What conditions does trial NCT07144813 study?
This clinical trial studies the following conditions: Urinary Urgency Incontinence.
What interventions are being tested in trial NCT07144813?
The interventions under investigation include: Neuspera Implantable Sacral Neuromodulation System (DEVICE).
Who is sponsoring clinical trial NCT07144813?
This trial is sponsored by Neuspera Medical, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07144813 being conducted?
This trial has 20 study locations across California, Florida, Indiana, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Urgency Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07144813's enrollment target sits among peer trials
116 808th of 2000 higher than 1,191 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI